Create a Free Account
or
Create a Free Account
or
| # | Filing Date | Period End Date | Type | Report Link |
|---|---|---|---|---|
| No Data found | ||||
| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
GSK's Q3 sales and earnings topped estimates, driven by Specialty Medicines and vaccines, prompting the firm to raise its 2...
GSK (NYSE:GSK) raises FY2025 Adj EPS guidance from $4.59 to $4.73-$4.81 vs $4.38 analyst estimate. Raises FY2025 sales outlook ...
GSK (NYSE:GSK) reported quarterly earnings of $1.48 per share which beat the analyst consensus estimate of $1.26 by 17.78 perce...
FDA approves GSK's Blenrep combo for relapsed multiple myeloma, showing 51% reduced death risk and tripled progression-free...
- Reuters
Alector's Phase 3 trial for FTD-GRN drug, latozinemab, failed the clinical co-primary endpoint. The program is discontinued...
Data confirm therapeutic equivalence and comparable safety profile for Ventolin (salbutamol) containing innovative low carbon p...
Data presented at IDWeek 2025 after study stopped early for efficacyPrimary endpoint met, demonstrating non-inferiority of oral...
